Journal Watch · ACS Nano · 2026
A Metabolic Nanoplatform Potentiates Triple-Negative Breast Cancer Radiosensitivity via Disrupting Carbonic Anhydrase IX/Pentose Phosphate Pathway Crosstalk.
This work advances the frontier of metabolism-targeted nanomedicine for precision cancer therapy, offering a promising strategy to combat radiotherapy resistance in aggressive breast cancer.
TL;DR
This work advances the frontier of metabolism-targeted nanomedicine for precision cancer therapy, offering a promising strategy to combat radiotherapy resistance in aggressive breast cancer.
Key findings
- Consequently, PGA effectively overcomes radioresistance and suppresses TNBC lung metastasis through the coordinated disruption of tumor metabolism and remodeling of the tumor immune microenvironment.
- This work advances the frontier of metabolism-targeted nanomedicine for precision cancer therapy, offering a promising strategy to combat radiotherapy resistance in aggressive breast cancer.
What they did
In addition, the high-Z element Gd endows PGA with potent radiosensitizing properties by enhancing X-ray absorption and DNA damage. In orthotopic and metastatic triple-negative breast cancer (TNBC) mouse models, PGA combined with radiotherapy markedly improves the therapeutic efficacy. Mechanistically, this metabolic reprogramming amplifies radiation-induced apoptosis and immunogenic cell death (ICD) while inhibiting metastasis-associated matrix metalloproteinases (MMPs) and the epithelial-mesenchymal transition (EMT) process.
Full abstract (original)
Background: Radiotherapy resistance in tumors driven by metabolic adaptations within acidic microenvironments involves the upregulation of both carbonic anhydrase IX (CA IX) and the pentose phosphate pathway (PPP) as well as the functional crosstalk between them. To overcome this, we developed a polyvinylpyrrolidone (PVP)-modified gadolinium acetazolamide (PGA) nanoradiosensitizer. PGA simultaneously inhibits CA IX to trigger intracellular acidification and tumor cell acidosis, suppresses PPP through regulation of glucose-6-phosphate dehydrogenase (G6PD), and depletes key radioresistance-sustaining metabolites, such as NADPH, lipids, and nucleotide precursors.
What they did: In addition, the high-Z element Gd endows PGA with potent radiosensitizing properties by enhancing X-ray absorption and DNA damage. In orthotopic and metastatic triple-negative breast cancer (TNBC) mouse models, PGA combined with radiotherapy markedly improves the therapeutic efficacy. Mechanistically, this metabolic reprogramming amplifies radiation-induced apoptosis and immunogenic cell death (ICD) while inhibiting metastasis-associated matrix metalloproteinases (MMPs) and the epithelial-mesenchymal transition (EMT) process.
Results & conclusions: Consequently, PGA effectively overcomes radioresistance and suppresses TNBC lung metastasis through the coordinated disruption of tumor metabolism and remodeling of the tumor immune microenvironment. This work advances the frontier of metabolism-targeted nanomedicine for precision cancer therapy, offering a promising strategy to combat radiotherapy resistance in aggressive breast cancer.
Abstract © the authors / ACS Nano (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1021/acsnano.6c06716 · PubMed 42915044.
Why it matters for pharma & biotech
- Relevant to Biotechnology & Methods teams tracking ACS Nano for new targets, mechanisms and biomarkers.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this ACS Nano study find?
This work advances the frontier of metabolism-targeted nanomedicine for precision cancer therapy, offering a promising strategy to combat radiotherapy resistance in aggressive breast cancer.
What type of study is this?
It is a preclinical (animal / model) study, published in ACS Nano in 2026. In addition, the high-Z element Gd endows PGA with potent radiosensitizing properties by enhancing X-ray absorption and DNA damage.
Where can I read the original paper?
The original is at the publisher via DOI 10.1021/acsnano.6c06716. PubMed ID: 42915044. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/a-metabolic-nanoplatform-potentiates-triple-negative-breast-cancer-radio-c06716/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides